Revive Therapeutics Ltd Stock Price, News & Analysis

Revive Therapeutics Ltd. (OTCQB: RVVTF) has received positive feedback from the FDA regarding the Phase 3 clinical trial of Bucillamine for mild to moderate COVID-19 patients. The FDA agreed to potential new primary efficacy endpoints aimed at improving clinical outcomes. The company will unblind data from the first 210 patients after submitting a Data Access Plan. The Data Safety and Monitoring Board previously supported the study's continuation, citing no serious safety concerns. The firm emphasizes the urgent need for effective treatments amid the ongoing COVID-19 pandemic.

Revive Therapeutics Ltd. has submitted a request to the FDA for new clinical endpoints in a Phase 3 trial evaluating Bucillamine for COVID-19 treatment. The request aims for primary efficacy endpoints focused on sustained symptom resolution. With COVID-19 hospitalizations declining, the Company emphasizes the need for effective symptom management. A Data Safety and Monitoring Board meeting is scheduled for June 2022 to assess interim data, possibly recommending continuation or early halting of the study. The Company clarifies it does not claim to eliminate COVID-19.

Revive Therapeutics (OTCQB: RVVTF) provided an update on its FDA Phase 3 clinical trial for Bucillamine, targeting mild to moderate COVID-19. The company is engaged with BARDA to explore funding options for advanced development. Revive aims to establish primary and secondary endpoints for FDA consideration, possibly leading to Emergency Use Authorization. CEO Michael Frank noted promising discussions with BARDA, reinforcing Bucillamine's potential as a treatment. However, there are no claims that Bucillamine can cure COVID-19 at this stage.

Revive Therapeutics Ltd. (OTCQB: RVVTF) has published a new scientific article that evaluates the impact of medications, particularly Bucillamine, on the antibody response to SARS-CoV-2 mRNA vaccines among Japanese patients with rheumatic diseases. The study found that antibody levels were significantly lower in patients treated with TNF inhibitors compared to those receiving Bucillamine. Bucillamine, currently in a Phase 3 clinical trial for COVID-19, displays anti-inflammatory and antiviral properties. The company plans to seek FDA Emergency Use Authorization.

Revive Therapeutics Ltd. (OTCQB: RVVTF) announced updates regarding its FDA Phase 3 clinical trial for Bucillamine, an oral medication targeting mild to moderate COVID-19. The Data Safety and Monitoring Board will evaluate the trial data this quarter, potentially leading to recommendations or early termination based on positive outcomes. The company aims to meet revised clinical endpoints for Emergency Use Authorization while continuing to enroll participants in the U.S. and Turkey, targeting completion by Q2-2022. CEO Michael Frank highlights the urgent need for effective oral treatments amid rising COVID-19 cases.

Revive Therapeutics Ltd. (OTCQB: RVVTF) reports progress in its Phase 3 clinical trial evaluating Bucillamine for mild to moderate COVID-19. The study, in collaboration with Delta Health, targets 13 clinical sites in Turkey, aiming for full enrollment by Q2-2022. Revive plans to seek data safety monitoring board (DSMB) approval to proceed with an Emergency Use Authorization (EUA) application to the FDA. The company emphasizes the continuous need for effective treatments amidst emerging COVID-19 variants.

Revive Therapeutics Ltd. (OTCQB: RVVTF) announced that the U.S. FDA granted Orphan Drug Designation for Bucillamine to prevent ischemia–reperfusion injury (IRI) during liver transplantation. Currently, no approved treatments exist for IRI, a significant complication after liver transplants. Bucillamine could improve patient outcomes and expand the availability of quality organs for transplantation. Orphan Drug Designation provides various incentives, including seven years of exclusivity and tax credits for clinical trials, emphasizing Revive's commitment to addressing rare medical needs.

Revive Therapeutics Ltd. (OTCQB: RVVTF) has received Ethics Committee approval for its Phase 3 clinical trial in Turkey to evaluate Bucillamine, an oral treatment for mild to moderate COVID-19. The trial, conducted in partnership with Delta Health, will utilize 13 clinical sites, including major hospitals and research institutions. Turkey's ongoing battle with COVID-19, with 12.8 million infections, amplifies the urgency of this study. CEO Michael Frank emphasized this expansion supports enrollment goals and commercialization strategies for Revive's therapeutic initiatives.

Revive Therapeutics Ltd. (OTCQB: RVVTF) reported progress in its Phase 3 clinical trial for Bucillamine, targeting mild to moderate COVID-19. To date, 701 subjects have been dosed. The company is expanding enrollment into Turkey, partnering with MLP Care to leverage 30 research sites. Revive aims to complete enrollment by Q1-2022 and is preparing regulatory submissions for FDA and international approval. CEO Michael Frank emphasized the focus on finalizing enrollment and securing marketing agreements.